MALACHITE INNOVATIONS REPORTS SECOND QUARTER 2023 RESULTS

Rhea-AI Summary

Malachite Innovations, Inc. reports positive net income for the first time in its history. The company has achieved record sales and generated positive Adjusted EBITDA. Financial highlights include a significant increase in revenue, gross profit, and operating income.

Positive

• Malachite Innovations, Inc. has earned positive net income for the first time in its history. The company has achieved record sales and generated positive Adjusted EBITDA. Revenue increased by $3,358,908 in the second quarter of 2023 compared to the same period last year. Gross profit increased by $780,149 in the same period. Operating income improved by $524,956. Net income improved by $479,948. Adjusted EBITDA improved by $847,210. These positive financial results indicate the company's ability to execute its shareholder value creation plan.

Negative

• None.

CLEVELAND, OHIO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- MALACHITE INNOVATIONS, INC. (OTC Mkts: MLCT) (“Malachite”), a public company focused on improving the health and wellness of people and the planet, reported its results for the quarter ended June 30, 2023.

Malachite’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 was filed with the Securities and Exchange Commission on August 1, 2023 and is available for viewing at https://malachiteinnovations.com/investors/. Since the information provided in this press release is limited to selected financial and operational information, investors and interested parties are encouraged to read Malachite’s full Form 10-Q available on its website.

Michael Cavanaugh, Malachite’s CEO, commented, “I am proud to report that the Company has earned positive net income from ordinary course operations for the very first time in its more than 11-year history as a public company.” Cavanaugh continued, “Additionally, with our 2Q 2023 results, Malachite has now posted its fourth consecutive quarter of record sales and has generated positive Adjusted EBITDA of $1,259,642 during the 12-month period ended 2Q 2023, which shatters the prior record of positive Adjusted EBITDA of $412,437 earned during the 12-month period ended 1Q 2023. Although we believe that these early results validate our impact investing strategy and evince our ability to execute our shareholder value creation plan, our current size and financial performance represents only a small fraction of our ultimate vision for the Company. Therefore, our entire team remains focused and determined to work every day to create a truly unique business that helps people and communities, improves the environment, and financially rewards our shareholders.”

Second Quarter 2023 Financial Highlights

• Revenue | $3,998,267 in 2Q 2023 versus $639,359 in 2Q 2022, an increase of $3,358,908, and $11,206,073 in the last 12-month (“LTM”) period ending June 30, 2023 versus $639,359 in the LTM period ending June 30, 2022, an increase of $10,566,714.
  
• Gross Profit | $845,101 in 2Q 2023 versus $64,952 in 2Q 2022, an increase of $780,149, and $2,822,403 in the LTM period ending June 30, 2023 versus $64,952 in the LTM period ending June 30, 2022, an increase of $2,757,451.
  
• Operating Income (Loss) | $101,759 in 2Q 2023 versus ($423,197) in 2Q 2022, an improvement of $524,956, and ($315,029) in the LTM period ending June 30, 2023 versus ($1,967,318) in the LTM period ending June 30, 2022, an improvement of $1,652,289.
  
• Net Income (Loss) | $36,762 in 2Q 2023 versus ($443,186) in 2Q 2022, an improvement of $479,948, and ($371,114) in the LTM period ending June 30, 2023 versus ($1,991,894) in the LTM period ending June 30, 2022, an improvement of $1,620,780.
  
• Adjusted EBITDA | $479,405 in 2Q 2023 versus ($367,805) in 2Q 2022, an improvement of $847,210, and $1,259,642 in the LTM period ending June 30, 2023 versus ($1,660,765) in the LTM period ending June 30, 2022, an improvement of $2,920,407.
  
• Cash Flow from Operations | ($1,074,195) in 2Q 2023 versus ($450,887) in 2Q 2022, a decline of ($623,308), and ($157,109) in the LTM period ending June 30, 2023 versus ($1,648,111) in the LTM period ending June 30, 2022, an improvement of $1,491,002.
  

Second Quarter 2023 Consolidated Financial Highlights

		2Q 2023				2Q 2022				2Q 2023 LTM				2Q 2022 LTM
Revenue		$	3,998,267			$	639,359			$	11,206,073			$	639,359
Cost of Goods Sold			3,153,166				574,407				8,383,670				574,407
Gross Profit			845,101				64,952				2,822,403				64,952
Operating Expenses			743,342				488,149				3,137,432				2,032,270
Operating Income (Loss)			101,759				(423,197	)			(315,029	)			(1,967,318	)
Other Income			(64,997	)			(19,989	)			(56,085	)			(24,576	)
Net Income (Loss)			36,762				(443,186	)			(371,114	)			(1,991,894	)
Non-Cash Expenses			377,646				55,392				1,465,241				306,837
Working Capital Changes			(1,488,603	)			(63,093	)			(1,251,236	)			36,946
Cash Flow from Operations		$	(1,074,195	)		$	(450,887	)		$	(157,109	)		$	(1,648,111	)
Gross Profit Margin %			21.1	%			10.2	%			25.2	%			10.2	%
Operating Profit Margin %			2.5	%			-66.2	%			-2.8	%			-307.7	%
Net Income Margin %			0.9	%			-69.3	%			-3.3	%			-311.5	%
Cash Flow from Operations Margin %			-26.9	%			-70.5	%			-1.4	%			-257.8	%

Second Quarter 2023 Segmented Financial Highlights

		2Q 2023				2Q 2022				2Q 2023 LTM				2Q 2022 LTM
Revenue
Environmental		$	3,882,492			$	639,359			$	11,063,898			$	639,359
Biochar			-				-				-				-
Mitigation Banking			-				-				-				-
Security			115,775				-				142,175				-
Drug Development			-				-				-				-
Corporate			-				-				-				-
Total Revenue		$	3,998,267			$	639,359			$	11,206,073			$	639,359
Gross Profit
Environmental		$	789,687			$	64,952			$	2,756,566			$	64,952
Biochar			-				-				-				-
Mitigation Banking			-				-				-				-
Security			55,414				-				65,837				-
Drug Development			-				-				-				-
Corporate			-				-				-				-
Total Gross Profit		$	845,101			$	64,952			$	2,822,403			$	64,952
Net Income (Loss)
Environmental		$	433,922			$	(39,429	)		$	1,497,180			$	(77,630	)
Biochar			(19,116	)			-				(38,280	)			-
Mitigation Banking			-				-				-				-
Security			37,550				-				20,445				-
Drug Development			(107,444	)			(107,823	)			(450,871	)			(434,666	)
Corporate			(308,150	)			(295,934	)			(1,399,588	)			(1,479,598	)
Total Net Income (Loss)		$	36,762			$	(443,186	)		$	(371,114	)		$	(1,991,894	)
Adjusted EBITDA
Environmental		$	835,392			$	26,986			$	2,677,681			$	(11,215	)
Biochar			(18,690	)			-				(37,854	)			-
Mitigation Banking			-				-				-				-
Security			40,665				-				24,988				-
Drug Development			(107,444	)			(107,823	)			(450,871	)			(434,666	)
Corporate			(270,518	)			(286,968	)			(954,302	)			(1,214,884	)
Total Adjusted EBITDA		$	479,405			$	(367,805	)		$	1,259,642			$	(1,660,765	)

Second Quarter 2023 Reconciliation of Net Income (Loss) to Adjusted EBITDA

		2Q 2023				2Q 2022				2Q 2023 LTM				2Q 2022 LTM
Net Income (Loss)
Environmental		$	433,922			$	(39,429	)		$	1,497,180			$	(77,630	)
Biochar			(19,116	)			-				(38,280	)			-
Mitigation Banking			-				-				-				-
Security			37,550				-				20,445				-
Drug Development			(107,444	)			(107,823	)			(450,871	)			(434,666	)
Corporate			(308,150	)			(295,934	)			(1,399,588	)			(1,479,598	)
Total Net Income (Loss)		$	36,762			$	(443,186	)		$	(371,114	)		$	(1,991,894	)
Interest
Environmental		$	63,061			$	11,023			$	149,185			$	11,023
Biochar			-				-				-				-
Mitigation Banking			-				-				-				-
Security			224				-				224				-
Drug Development			-				-				-				-
Corporate			1,712				8,966				16,106				13,269
Total Interest		$	64,997			$	19,989			$	165,515			$	24,292
Taxes
Environmental		$	-			$	-			$	-			$	-
Biochar			-				-				-				-
Mitigation Banking			-				-				-				-
Security			-				-				-				-
Drug Development			-				-				-				-
Corporate			-				-				-				-
Total Taxes		$	-			$	-			$	-			$	-
Depreciation
Environmental		$	338,409			$	55,392			$	1,031,316			$	55,392
Biochar			426				-				426				-
Mitigation Banking			-				-				-				-
Security			2,891				-				4,319				-
Drug Development			-				-				-				-
Corporate			-				-				-				-
Total Depreciation		$	341,726			$	55,392			$	1,036,061			$	55,392
Non-Cash Charges
Environmental		$	-			$	-			$	-			$	-
Biochar			-				-				-				-
Mitigation Banking			-				-				-				-
Security			-				-				-				-
Drug Development			-				-				-				-
Corporate			35,920				-				429,180				251,445
Total Non-Cash Charges		$	35,920			$	-			$	429,180			$	251,445
Adjusted EBITDA
Environmental		$	835,392			$	26,986			$	2,677,681			$	(11,215	)
Biochar			(18,690	)			-				(37,854	)			-
Mitigation Banking			-				-				-				-
Security			40,665				-				24,988				-
Drug Development			(107,444	)			(107,823	)			(450,871	)			(434,666	)
Corporate			(270,518	)			(286,968	)			(954,302	)			(1,214,884	)
Total Adjusted EBITDA		$	479,405			$	(367,805	)		$	1,259,642			$	(1,660,765	)

Non-GAAP Financial Information

In addition to our results under Generally Accepted Accounting Principles (“GAAP”), in this release we also present certain other supplemental measures of financial performance that are not required by or presented in accordance with GAAP, including Adjusted Earnings Before Interest Taxes Depreciation and Amortization (“Adjusted EBITDA”). We calculate Adjusted EBITDA as net income (loss) before interest expense, income tax expense, depreciation and amortization, and non-cash stock-based compensation expenses related to restricted stock grants and stock options issued to directors and employees and consultants. Adjusted EBITDA is one of the primary metrics used by management to evaluate our financial performance, analyze the effectiveness of our business strategies, and make budgeting and capital allocation decisions. However, this non-GAAP measure does have certain limitations and should not be considered as an alternative to net income (loss), earnings (loss) per share or any other performance measures derived in accordance with GAAP.

About Malachite Innovations, Inc.

Headquartered in Cleveland, Ohio, Malachite Innovations, Inc. is a public holding company dedicated to improving the health and wellness of people and the planet through a novel and innovative approach to impact investing. Malachite owns and operates a balanced portfolio of operating businesses focused on developing long-term solutions to environmental, social and health challenges, with a particular focus on economically disadvantaged communities. Malachite takes an opportunistic approach to impact investing by leveraging its competitive advantages and looking at solving old problems in new ways. Malachite seeks to thoughtfully allocate its capital into ventures that are expected to make a positive impact on the people-planet ecosystem and generate strong investment returns for its shareholders.

Notice Regarding Forward-Looking Statements

This press release contains “forward-looking statements” as that term is defined in Section 27(a) of the Securities Act of 1933, as amended and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Although we believe that these statements are based on reasonable assumptions, they are subject to numerous factors that could cause actual outcomes and results to be materially different from those indicated in such statements. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies, timing of clinical trials and product development, business strategy and new lines of business. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

Malachite Innovations, Inc.
Investor Relations
P: +1 (216) 304-6556
E: ir@malachiteinnovations.com
W: www.malachiteinnovations.com

FAQ

What are Malachite Innovations' financial highlights for the second quarter of 2023?

In the second quarter of 2023, Malachite Innovations achieved significant financial growth. Revenue increased by $3,358,908, gross profit increased by $780,149, operating income improved by $524,956, net income improved by $479,948, and Adjusted EBITDA improved by $847,210 compared to the same period last year.

What is the significance of Malachite Innovations earning positive net income?

Earning positive net income for the first time in its history is a significant milestone for Malachite Innovations. It demonstrates the company's ability to generate profits from its ordinary course operations and validates its impact investing strategy.

How many consecutive quarters of record sales has Malachite Innovations achieved?

Malachite Innovations has achieved four consecutive quarters of record sales, including the second quarter of 2023.

What is Malachite Innovations' vision for the future?

Malachite Innovations aims to create a unique business that improves the health and wellness of people and the planet, helps communities, and financially rewards its shareholders. The company's current size and financial performance represent only a small fraction of its ultimate vision.